Terms: = Liver cancer AND PRKACA, MGC48865, 5566, ENSG00000072062, P17612, PKACA, MGC102831 AND Treatment
17 results:
1. Anti-Tumor Activity and Mechanism of Silibinin Based on Network Pharmacology and Experimental Verification.
Li P; Wang D; Yang X; Liu C; Li X; Zhang X; Liu K; Zhang Y; Zhang M; Wang C; Wang R
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675723
[TBL] [Abstract] [Full Text] [Related]
2. DNAJB1-prkaca fusion neoantigens elicit rare endogenous TÂ cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
[TBL] [Abstract] [Full Text] [Related]
3. GalNAc-conjugated siRNA targeting the DNAJB1-prkaca fusion junction in fibrolamellar hepatocellular carcinoma.
Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
[TBL] [Abstract] [Full Text] [Related]
4. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
Kim J; Kim Y; Lee B
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
[TBL] [Abstract] [Full Text] [Related]
5. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract] [Full Text] [Related]
6. Successful liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract] [Full Text] [Related]
7. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract] [Full Text] [Related]
8. Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
El Dika I; Bowman AS; Berger MF; Capanu M; Chou JF; Benayed R; Zehir A; Shia J; O'Reilly EM; Klimstra DS; Solit DB; Abou-Alfa GK
Cancer; 2020 Sep; 126(18):4126-4135. PubMed ID: 32663328
[TBL] [Abstract] [Full Text] [Related]
9. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the treatment of Patients with Advanced Fibrolamellar Carcinoma.
Abou-Alfa GK; Mayer R; Venook AP; O'Neill AF; Beg MS; LaQuaglia M; Kingham PT; Kobos R; Basturk O; Brennan C; Yopp A; Harding JJ; Leong S; Crown J; Hoti E; Leonard G; Ly M; Bradley M; Valentino E; Markowitz D; Zukiwski A; Ren K; Gordan JD
Oncologist; 2020 Dec; 25(12):e1837-e1845. PubMed ID: 32154962
[TBL] [Abstract] [Full Text] [Related]
10. DNAJB1-prkaca fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract] [Full Text] [Related]
11. Single-Cell RNA Sequencing Identifies Yes-Associated Protein 1-Dependent Hepatic Mesothelial Progenitors in Fibrolamellar Carcinoma.
Jewell ML; Gibson JR; Guy CD; Hyun J; Du K; Oh SH; Premont RT; Hsu DS; Ribar T; Gregory SG; Diehl AME
Am J Pathol; 2020 Jan; 190(1):93-107. PubMed ID: 31669305
[TBL] [Abstract] [Full Text] [Related]
12. Fibrolamellar Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Multidisciplinary Therapy.
Tanaka H; Hijioka S; Iwaya H; Mizuno N; Kuwahara T; Okuno N; Ito A; Kuraoka N; Matsumoto S; Obata M; Kurita Y; Yasuda M; Shimizu Y; Kuroda H; Sato Y; Haneda M; Sasaki E; Yatabe Y; Hara K
Intern Med; 2018 Dec; 57(24):3537-3543. PubMed ID: 30101933
[TBL] [Abstract] [Full Text] [Related]
13.
Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
[TBL] [Abstract] [Full Text] [Related]
14. Emerging molecular therapeutic targets for cholangiocarcinoma.
Rizvi S; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract] [Full Text] [Related]
15. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
Graham RP; Torbenson MS
Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
[TBL] [Abstract] [Full Text] [Related]
16. FGFR1 and FGFR2 in fibrolamellar carcinoma.
Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
[TBL] [Abstract] [Full Text] [Related]
17. Advances in fibrolamellar hepatocellular carcinoma: a review.
Lim II; Farber BA; LaQuaglia MP
Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
[TBL] [Abstract] [Full Text] [Related]
